Enterprise News

The company participated in the 5th International Conference on Vaccine Antibody

From March 18 to 20, 2013, leaders of EBVAC R&D Center and technical managers of all departments participated in the 5th International Conference on Vaccine Antibody held in Hangzhou.

The theme of this conference is: better innovation and global health. The conference delivered special reports and held discussion on the six main subjects including global infectious disease prevention and public health, vaccine science and technology, global vaccine production, manufacture and market development, vaccines for human use (infectious diseases), vaccines for human use (non-communicable diseases) and livestock and fisheries veterinary vaccines.

Participants of the company paid close attention to global immunization programs and alliances, new strategies for infectious disease prevention, fundamental vaccine science and technology, viral vaccine vector, development of nanotechnology vaccine and T-cell memory vaccine, the new vaccine adjuvant and delivery systems, vaccine clinical trials, and innovative vaccines and technology. They also actively communicated and discussed with some experts on relevant themes.

Under its core values of “Innovation, Evolution and Quality”, the company aims to achieve the improvement and development of its technical force through its cutting-edge technologies, keen insight into the latest industry development trendy and innovative practice, and provide customers with pure, safe and efficient products by developing new products and optimizing technological process.

Related News

  • •  The company’s 1st Zhejiang Partner Technical Forum and “Yuanjingnuo (PCV type II)” Launch Conference was successfully held

    With willows swaying in the wind and trees shading the street, the spring has come to Hangzhou. From April 13 to 14, the company held its first Zhejiang Partner Technical Forum and “Yuanjingnuo” Launch Conference. Famous industry experts, leaders of the Animal Husbandry and Veterinary Bureau and Animal Disease Control Center, entrepreneurs of large ranch, technicians and dealersdistributors of EBVAC participated in the conference and celebrated the successful launch of Yuanjingnuo. During the conference, Professor Zhou Jiyong, the designer of porcine circovirus ZJ / C strains and Director of Animal Virology of the Ministry of Agriculture Key Laboratory of Zhejiang University, Researcher Wang Yicheng, Director of the Swine Disease Research Center of Zhejiang Academy of Agricultural Sciences and Professor Li Baochen, General Manager of the company delivered report to the participants.

  • •  EBVAC Yuanjingnuo is now on sale

    EBVAC new featured product “Yuanjingnuo”- porcine circovirus type 2 inactivated vaccine (ZJ / C strain) has achieved the new veterinary drug registration certificates and veterinary approval number of Ministry of Agriculture and will be launched in the spring of 2013.

  • •  To establish a first-class, independent and innovative new enterprise EBVAC is setting sail

    “Innovation, Evolution and Quality”, since its inception, EBVAC has been steadfastly working on independent innovation. In order to develop high-quality animal vaccine products, apart from establishing the first-class R&D Center within the industry (identified as Zhejiang high-tech R&D Center in 2009), the company has been actively looking for benchmark and gaps with its competitors, adopting innovative ideology from other outstanding enterprises and bringing in a large number of industry elites with innovation capacity. Through years of efforts, the company has created a number of products with intellectual property rights as well as innovations in processing.

  • •  Delegation from Doumen District in Zhuhai City visited our company for research

    On 15th March 2013, delegation from Doumen District in Zhuhai City accompanied by relevant readers of Xiasha Economic and Technological Development Zone, visited our company for investigation. During the investigation, Manger Lv briefly introduced the positioning development, corporate culture and values, quality pursuit and market expansion of the company. The company management conducted in-depth discussions with the members of the delegation on issues such as biosafety control, declaration for new veterinary and application for government-funded projects.

  • •  The company was successively awarded New Veterinary Registration Certificates of three vaccines including the “porcine circovirus type 2 (ZJ / C strain) inactivated vaccine”.

    At the beginning of 2013, the company was successively awarded New Veterinary Registration Certificates of three vaccines including porcine circovirus type 2 (ZJ / C strain) inactivated vaccine developed in cooperation with the Key Laboratory of Virology of the Ministry of Agriculture, Zhejiang University; three types of new veterinary drug of duck infectious serositis bivalent inactivated vaccine (type 1 SG4strain+type 2 ZZY7strain) developed in cooperation with China Agricultural University; two types of new veterinary drug of duck hepatitis live vaccine developed in cooperation with Anhui Animal Science Institute of Academy of Agricultural Sciences, Jiangsu Veterinary Research Institute of Academy of Agricultural Sciences and National Research Center of Veterinary Biologicals engineering and technology.

  • •  Always be alert

    -Record of EBVAC Safety Work Conference in the First Quarter of 2013